New Study Will Assess Viability of MDMA-Assisted Therapy to Treat Eating Disorders

Article by Sam Riches, Growth Op

News Reviews Life Wellness Videos Cannabis Post Breadcrumb Trail Links WellnessNewsMedicalHealth New study will assess viability of MDMA-assisted therapy to treat eating disorders Field Trip Health’s Toronto location will be used as the trial site for the anorexia nervosa portion of the study. Author of the article:Sam Riches The reception area of Field Trip Health's Toronto location. / PHOTO BY FIELD TRIP HEALTH LTD The Multidisciplinary Association for Psychedelic Studies (MAPS), a non-profit research and educational organization, is sponsoring a new study on the safety, feasibility and preliminary outcomes of MDMA-assisted therapy in treat eating disorders, including anorexia nervosa.

The Multidisciplinary Association for Psychedelic Studies (MAPS), a non-profit research and educational organization, is sponsoring a new study on the safety, feasibility and preliminary outcomes of MDMA-assisted therapy in treat eating disorders, including anorexia nervosa.

Field Trip Health Ltd., which opened its first Canadian clinic in Toronto last year, will also be participating in the latest MAPS study.

Subject to a final site inspection, Field Trip’s Toronto location will be used as the trial site for the anorexia nervosa portion of the study, the company announced in a statement.

“Anorexia nervosa is a mental health condition and eating disorder characterized by low weight, food restriction, fear of gaining weight and a strong desire to be thin,” the release states. “Anorexia is also the most deadly mental illness, with a higher mortality (death) rate than any other mental illness, leading to potential cardiac complications, heart, kidney and liver failure, bone loss, anemia and suicide.”

Field Trip’s Canadian medical director, Dr. Michael Verbora, will act as the site physician. MAPS-trained therapists will be working out of the Toronto location, providing MDMA-assisted therapy to those suffering from anorexia nervosa, and collecting safety, feasibility and preliminary outcome data.

Founded in 1986, MAPS has raised more than $100 million for psychedelic therapy and medical marijuana research and education. MAPS is currently in Phase 3 clinical trials assessing the safety and efficacy of MDMA-assisted therapy for the treatment of post-traumatic stress disorder (PTSD).

In Phase 2 trials, working with 107 participants who have chronic, treatment-resistant PTSD, 61 per cent no longer qualified for PTSD following three sessions of MDMA-assisted therapy.

“MAPS, led by Rick Doblin’s unique vision and relentless determination, has been at the forefront of the renaissance of psychedelics, pushing for scientific, regulatory and legal change for psychedelics for more than 30 years,” says Ronan Levy, Field Trip’s executive chairman.

In the same release, Field Trip also announced that it will be making an annual $50,000 donation to support MAPS, “which will be matched by a collective contribution from the founders of Field Trip on a dollar-for-dollar basis.”

Read the full article here.

About Dankr NewsBot

Beep Boop. I'm just a bot who brings you the dankest news in the biz

Leave a Reply

Powered by Dragonballsuper Youtube Download animeshow